Oncotelic Therapeutics (OTLC) AI Stock Analysis

• Market Cap: $20.71M
• Dividend Yield: N/A
• Average Volume (3M): 114.20K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.22
• Revenue Growth: -100.00%
• EPS Growth: 44.50%
• Country: US
• Employees: 26
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 408,292,450
• 10 Day Avg. Volume: 199,337
• 30 Day Avg. Volume: 114,203
• PEG Ratio: -0.63
• Price to Book (P/B): 3.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -37.95
• Enterprise Value/Market Cap: 1.99
• Enterprise Value/Revenue: 588.15
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -3.40
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: ―

Oncotelic Therapeutics' stock is facing substantial challenges, primarily driven by poor financial performance due to a lack of revenue and high leverage. While technical indicators show some positive momentum, the valuation remains unattractive with negative earnings. Overall, strategic changes are necessary to improve the company's financial health and investment appeal.

Oncotelic Therapeutics Business Overview & Revenue Model

Company Description

Oncotelic Therapeutics, Inc. (OTLC) is a biotechnology company focused on developing novel therapies for the treatment of cancer. The company operates within the healthcare sector, concentrating on oncology therapeutics. Its core products include investigational drugs and treatments targeting tumor progression and metastasis, with a particular emphasis on RNA therapeutics and immuno-oncology approaches.

How the Company Makes Money

Oncotelic Therapeutics primarily generates revenue through the development and commercialization of its therapeutic candidates. The company's revenue model includes securing funding through partnerships, grants, and licensing agreements with other pharmaceutical companies and research institutions. Additionally, Oncotelic may earn revenue through milestone payments and royalties from successful collaborations and the eventual commercialization of its drug candidates. The company's earnings are significantly influenced by its ability to advance its drugs through clinical trials and achieve regulatory approvals, which can lead to increased licensing opportunities and partnerships.

Oncotelic Therapeutics Financial Statement Overview

Summary

Oncotelic Therapeutics faces significant financial challenges, primarily due to its inability to generate revenue, leading to persistent losses and reliance on external financing. The high debt levels increase the financial risk, and negative cash flow from operations underscores the urgent need for strategic changes to improve financial health and sustainability.

Income Statement

The income statement reveals significant challenges for Oncotelic Therapeutics. The company has experienced a consistent lack of revenue, with total revenue falling to zero in the most recent year, indicating no product sales or service revenues. Net profit margin is heavily negative due to substantial net losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Overall, the financials suggest significant profitability issues that need addressing.

Balance Sheet

The balance sheet shows moderate financial stability. The debt-to-equity ratio increased to approximately 1.99, indicating a relatively high level of leverage which could pose risk if revenue generation does not improve. However, the company maintains a reasonable equity ratio of 30.9%, suggesting some strength in its asset base. The increase in total liabilities suggests growing financial obligations.

Cash Flow

Cash flow analysis indicates cash management challenges. Operating cash flow remains negative, reflecting poor cash generation from core operations. The free cash flow is also negative, highlighting insufficient operating cash to support capital expenditures. However, there was a significant inflow from financing activities, suggesting reliance on external funding, which is not sustainable long-term without revenue improvement.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	70.00K	0.00	0.00	1.74M
Gross Profit	0.00	70.00K	-12.84K	-61.51K	1.74M
EBITDA	-3.58B	-7.16M	-5.60M	-9.06M	-7.61M
Net Income	-4.52B	-7.90M	17.82M	-11.39M	-11.50M
Balance Sheet
Total Assets	26.68M	30.01M	36.12M	23.61M	23.66M
Cash, Cash Equivalents and Short-Term Investments	86.13K	170.41K	241.45K	568.77K	474.02K
Total Debt	13.09M	12.57M	11.26M	8.99M	5.43M
Total Liabilities	19.20M	18.40M	16.92M	15.45M	11.18M
Stockholders Equity	8.25M	12.13M	19.41M	7.96M	11.77M
Cash Flow
Free Cash Flow	-740.27K	-1.32M	-1.45M	-4.43M	-2.81M
Operating Cash Flow	-740.27K	-1.32M	-1.45M	-4.43M	-2.81M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	656.00K	1.25M	1.13M	4.53M	3.22M

Oncotelic Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLC, the sentiment is Neutral. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.75 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OTLC.

Oncotelic Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PULM	53 Neutral	$22.68M	―	-93.19%	―	6.96%	32.32%
Sector *	52 Neutral	$7.37B	-0.04	-63.81%	2.59%	16.40%	<0.01%
OTLC	44 Neutral	$20.71M	―	-44.46%	―	-100.00%	44.50%
CGTX	41 Neutral	$40.54M	―	-161.93%	―	―	-0.38%
TPST	39 Underperform	$25.73M	―	-282.07%	―	―	-220.54%
ANVS	35 Underperform	$51.64M	―	-280.78%	―	―	68.75%
ELEV	33 Underperform	$22.21M	―	-78.32%	―	―	47.73%